BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MyoScience Inc. Raises $33 Million Series D Financing


3/21/2012 7:17:51 AM

REDWOOD CITY, Calif., March 21, 2012 /PRNewswire/ -- Venture-backed myoscience, Inc. announced that it closed on $33 million in Series D financing and anticipates a second tranche of up to $12 million dollars due to significant interest in the investment community. Myoscience is committed to making its platform technology, focused cold therapy (FCT), the pre-eminent treatment for conditions involving nerves. The company will use the proceeds of the current financing round to commercialize the first indication in Europe, which is a treatment to reduce 'dynamic facial lines,' more commonly referred to as forehead wrinkles. Toxin-free FCT is uniquely positioned to expand the aesthetic market for treatment of dynamic facial lines currently addressed by neurotoxins.

Myoscience's strategy is to establish FCT as a platform technology for multiple indications, starting with the treatment of dynamic facial lines. The company then plans to expand the technology into therapeutic indications for the focal treatment of pain and muscle disorders. The company believes the addressable aesthetic market is approximately $2 billion while the market for the focal treatment of pain and muscle disorders may be up to $9 billion.

"Our financing was significantly oversubscribed -- a marker, we believe, of our company's significant progress this year and potential in the near future," said Clint Carnell, myoscience President & CEO. "We look forward to commercializing our aesthetic indication in Europe, and believe that our natural, non-toxin approach will expand the entire category by pulling toxin-averse patients off the sidelines and into the doctor's office. With the platform complete we can now work with physicians to develop non-addictive, non-injectable treatments for various therapeutic applications in pain and muscle disorders, an equally exciting and compelling market for our unique technology."

The Series D financing included the following existing investors: Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Nexus Medical Partners, Saratoga Ventures, and Valiance.

Myoscience received CE Mark clearance and its Canadian market license in December 2011 for temporary treatment of wrinkles and the treatment of pain. The company recently submitted a 510k application for the treatment of pain with the U.S. Food and Drug Administration, and will shortly begin to enroll subjects in a pivotal trial to support FDA clearance for treatment of wrinkles. The technology is presently cleared in the U.S. for treatment of peripheral pain syndromes and use in general tissue ablation.

About myoscience

Redwood City, California-based myoscience is a privately-held medical device company committed to making its platform technology, focused cold therapy (FCT), the pre-eminent treatment for conditions involving nerves. FCT is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions and focal cryo-treatment of tissue. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Company Contact: Clint Carnell, 650/421-0605

Media Contact: Steve DiMattia, 646/201-5445

SOURCE myoscience



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES